Alogliptin improves survival and health of mice on a high-fat diet

• Authors: Biao Zhu, Chinese Peoples Liberation Army General Hospital; Yixiang Li, Emory University; Lingwei Xiang, Allconnect Inc; Jiajia Zhang, Chinese Peoples Liberation Army General Hospital; Li Wang, Emory University; Bei Guo, Chinese Peoples Liberation Army General Hospital; Minglu Liang, Huazhong University of Science & Technology; Long Chen, Huazhong University of Science & Technology; Lin Xiang, Chinese Peoples Liberation Army General Hospital; Jing Dong, Chinese Peoples Liberation Army General Hospital; Min Liu, Chinese Peoples Liberation Army General Hospital; Wen Mei, Chinese Peoples Liberation Army General Hospital; Huan Li, Chinese Peoples Liberation Army General Hospital; Guangda Xiang, Chinese Peoples Liberation Army General Hospital
• Journal Title: Aging Cell
• Volume: Volume 18, Number 2
• Publisher: Wiley Open Access | 2019-04-01, Pages e12883-e12883
• Type of Work: Article | Final Publisher PDF
• Publisher DOI: http://doi.org/10.1111/acel.12883
• Subjects: Health Sciences, General; Biology, Cell
• Keywords: Science & Technology; Life Sciences & Biomedicine; Cell Biology; Geriatrics & Gerontology; DPP-4 inhibitor; GLP-1; healthspan; high-fat diet; longevity; DIPEPTIDYL PEPTIDASE-4 INHIBITOR; LEFT-VENTRICULAR DYSFUNCTION; GLUCAGON-LIKE PEPTIDE-1; LIFE-SPAN EXTENSION; BETA-CELL FUNCTION; INSULIN-RESISTANCE; LIPID-ACCUMULATION; AUTOPHAGY; SITAGLIPTIN; LIRAGLUTIDE

Abstract

Aging Cell published by the Anatomical Society and John Wiley & Sons Ltd. Alogliptin is a commonly prescribed drug treating patients with type 2 diabetes. Here, we show that long-term intervention with alogliptin (0.03% w/w in diet) improves survival and health of mice on a high-fat diet. Alogliptin intervention takes beneficial effects associated with longevity, including increased insulin sensitivity, attenuated functionality decline, decreased organ pathology, preserved mitochondrial function, and reduced oxidative stress. Autophagy activation is proposed as an underlying mechanism of these beneficial effects. We conclude that alogliptin intervention could be considered as a potential strategy for extending lifespan and healthspan in obesity and overweight.